Jang Min Soo, Baek Jae Woo, Park Jong Bin, Kang Dong Young, Kang Jin Seuk, Suh Kee Suck, Kim Sang Tae
Department of Dermatology, Kosin University College of Medicine, Busan, Korea.
Ann Dermatol. 2011 Nov;23(4):474-80. doi: 10.5021/ad.2011.23.4.474. Epub 2011 Nov 3.
Narrowband UVB (NBUVB) is currently used to treat early mycosis fungoides (MF). There are a number of reports on the efficacy and safety of NBUVB in Caucasians, but little data is available for Asians.
This study was designed to evaluate the effectiveness and safety of NBUVB for early stage MF in Korean patients.
We enrolled 14 patients (12 men, 2 women; age range, 10~64 years) with clinically and histologically proven MF. Three patients were stage IA, and the others were stage IB. The patients received NBUVB phototherapy three times a week. The starting dose was 70% of the minimal erythema dose and was increased in 20 percent increments if the previous treatment did not cause erythema. Clinical response, total number of treatments, total cumulative dose, duration of remission and side effects were investigated.
Eleven of 14 patients (78.6%) achieved complete remission within a mean of 15.36±5.71 weeks (range, 527 weeks), 31.0±7.4 treatments (range, 1639 treatments) and a mean cumulative UVB dose of 31.31±12.16 J/cm(2) (range, 11.4~46.8 J/cm(2)). Three of the 14 patients (21.4%) achieved a partial remission. After discontinuation of treatment, 6 of 11 patients (54.5%) with complete remission relapsed after a mean of 8.5±4.09 months. No serious adverse effects were observed except for hyperpigmentation (7/14, 50%).
Our data suggest that NBUVB therapy is safe and effective for the treatment of early stage MF in Korean patients.
窄谱中波紫外线（NBUVB）目前用于治疗早期蕈样肉芽肿（MF）。关于NBUVB在白种人中的疗效和安全性已有多篇报道，但针对亚洲人的数据较少。
本研究旨在评估NBUVB治疗韩国早期MF患者的有效性和安全性。
我们纳入了14例经临床和组织学证实为MF的患者（12例男性，2例女性；年龄范围10至64岁）。3例为IA期，其余为IB期。患者每周接受3次NBUVB光疗。起始剂量为最小红斑量的70%，如果先前治疗未引起红斑，则以20%的增量增加剂量。研究了临床反应、治疗总次数、总累积剂量、缓解持续时间和副作用。
14例患者中有11例（78.6%）在平均15.36±5.71周（范围5至27周）内达到完全缓解，接受了31.0±7.4次治疗（范围16至39次），平均累积UVB剂量为31.31±12.16 J/cm²（范围11.4至46.8 J/cm²）。14例患者中有3例（21.4%）达到部分缓解。停止治疗后，11例完全缓解患者中有6例（54.5%）在平均8.5±4.09个月后复发。除色素沉着（7/14，50%）外，未观察到严重不良反应。
我们的数据表明，NBUVB疗法治疗韩国早期MF患者安全有效。
